Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 furnished under Regulation FD, rather than formally filed under Exchange Act Section 18.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, rather than formally filed under Exchange Act Section 18
- Disclosure generally excluded from incorporation by reference into other SEC filings unless expressly referenced
Item EX-99.1 · Exhibit EX-99.1
- First patient enrolled in pivotal global Phase 3 IMPROVE-PAH trial, advancing IKT-001 toward potential NDA submission
- Adaptive two-part design: approximately 140 patients in Part A and approximately 346 in Part B
- Part A primary endpoint: PVR change at Week 24; Part B primary endpoint: 6MWD change at Week 24
- 12-week dose titration and FDA-confirmed adaptive design intended to optimize tolerability and dosing
- Trial expected across up to approximately 180 sites, with execution and enrollment remaining key investor risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.